Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1995 1
2008 2
2009 1
2011 1
2012 1
2014 1
2015 1
2016 2
2017 1
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G. Melosky B, et al. Among authors: morzycki w. Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Curr Oncol. 2018. PMID: 30464681 Free PMC article. Review.
Molecular profiling of non-small cell lung cancer.
Forsythe ML, Alwithenani A, Bethune D, Castonguay M, Drucker A, Flowerdew G, French D, Fris J, Greer W, Henteleff H, MacNeil M, Marignani P, Morzycki W, Plourde M, Snow S, Xu Z. Forsythe ML, et al. Among authors: morzycki w. PLoS One. 2020 Aug 5;15(8):e0236580. doi: 10.1371/journal.pone.0236580. eCollection 2020. PLoS One. 2020. PMID: 32756609 Free PMC article.
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Bebb DG, et al. Among authors: morzycki w. Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548824 Free PMC article.
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Alwithenani A, Bethune D, Castonguay M, Drucker A, Flowerdew G, Forsythe M, French D, Fris J, Greer W, Henteleff H, MacNeil M, Marignani P, Morzycki W, Plourde M, Snow S, Marcato P, Xu Z. Alwithenani A, et al. Among authors: morzycki w. PLoS One. 2021 May 6;16(5):e0251080. doi: 10.1371/journal.pone.0251080. eCollection 2021. PLoS One. 2021. PMID: 33956842 Free PMC article.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. Melosky B, et al. Among authors: morzycki w. Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9. Curr Oncol. 2016. PMID: 27330348 Free PMC article.
Adjuvant chemotherapy uptake in non-small cell lung cancer.
Younis T, Al-Fayea T, Virik K, Morzycki W, Saint-Jacques N. Younis T, et al. Among authors: morzycki w. J Thorac Oncol. 2008 Nov;3(11):1272-8. doi: 10.1097/JTO.0b013e318189f562. J Thorac Oncol. 2008. PMID: 18978562 Free article.
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L. Laurie SA, et al. Among authors: morzycki w. J Thorac Oncol. 2011 Nov;6(11):1950-4. doi: 10.1097/JTO.0b013e3182333df5. J Thorac Oncol. 2011. PMID: 22005473 Free article. Clinical Trial.
17 results